Naminidil

Naminidil
Clinical data
Other namesBMS-234303; BMS234303
Routes of
administration
Topical
Drug classATP-sensitive potassium channel opener; Vasodilator
ATC code
  • None
Identifiers
  • 1-cyano-3-(4-cyanophenyl)-2-[(2R)-3,3-dimethylbutan-2-yl]guanidine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H19N5
Molar mass269.352 g·mol−1
3D model (JSmol)
  • C[C@H](C(C)(C)C)N=C(NC#N)NC1=CC=C(C=C1)C#N
  • InChI=1S/C15H19N5/c1-11(15(2,3)4)19-14(18-10-17)20-13-7-5-12(9-16)6-8-13/h5-8,11H,1-4H3,(H2,18,19,20)/t11-/m1/s1
  • Key:PGYDRGZVXVVZQC-LLVKDONJSA-N

Naminidil (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name BMS-234303) is an ATP-sensitive potassium channel opener with vasodilator activity which was under development as a topical medication for the treatment of androgenic alopecia (pattern hair loss) but was never marketed. The drug was under development by Bristol-Myers Squibb and reached phase 2 clinical trials by 2001. One of the phase 2 trials compared naminidil, minoxidil, and placebo for alopecia. However, no results of the study appear to have been made available. Development of naminidil was discontinued by 2008. In terms of chemical structure, naminidil is a guanidine derivative and is structurally distinct from minoxidil.

Synthesis

Although patented versions of the synthesis exist (c.f. Lednicer book), the earliest recorded synthesis is for the racemic compound and dates back to 1992.

See also